drugset
Drugs / AZD1656
last change Sep 2022 re-read 9 days ago

AZD1656

Small molecule targets GCK via activation

Developed for
type 2 diabetes mellitus · COVID-19
Investigated by
AstraZeneca · Queen Mary University of London · St George Street Capital

Trials 24

today NCT04516759 · Ph 2 NCT05216172 · Ph 2 NCT01221545 · Ph 1 NCT01221519 · Ph 1 NCT01103622 · Ph 1 NCT01152385 · Ph 2 NCT01103609 · Ph 1 NCT01095991 · Ph 1 NCT01083212 · Ph 1 NCT01069926 · Ph 1 NCT01096940 · Ph 1 NCT01082120 · Ph 1 NCT01020123 · Ph 2 NCT00995787 · Ph 1 NCT00916604 · Ph 1 NCT00856908 · Ph 2 NCT00817271 · Ph 1 NCT00819884 · Ph 1 NCT00817778 · Ph 2 NCT00774553 · Ph 1 NCT00768105 · Ph 1 NCT00741689 · Ph 1 NCT00747175 · Ph 1 NCT00726427 · Ph 1
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 118 trials
Phase 1 NCT01221545 Oct 2010 → Jan 2011 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 1 NCT01221519 Sep 2010 → Jan 2011 hyperglycemia, type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 1 NCT01103622 Jun → Dec 2010 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 1 NCT01103609 Apr → Aug 2010 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 1 NCT01095991 Mar → May 2010 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 1 NCT01083212 Mar → Jun 2010 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 1 NCT01069926 Mar → Oct 2010 hypoglycemia AstraZeneca Completed No outcome recorded
Phase 1 NCT01096940 Mar → Aug 2010 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 1 NCT01082120 Feb → May 2010 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 1 NCT00995787 Oct 2009 → Feb 2010 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 26 trials · 2 missed
Phase 2 NCT04516759 Aug 2020 → Apr 2021 COVID-19 St George Street Capital Completed Missed primary
Phase 2 NCT05216172 Dec 2019 → Sep 2022 end stage renal failure, type 2 diabetes mellitus Queen Mary University of London Completed No outcome recorded
Phase 2 NCT01152385 May 2010 → May 2011 type 2 diabetes mellitus AstraZeneca Completed Missed primary
Phase 2 NCT01020123 Oct 2009 → Feb 2011 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 2 NCT00856908 Feb → Aug 2009 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 2 NCT00817778 Jan → Jul 2009 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded
Comparator or background therapy2 trials
Phase 1 NCT00817505 Comparator Dec 2008 → Mar 2009 type 1 diabetes mellitus AstraZeneca Completed No outcome recorded
Phase 1 NCT00790153 Comparator Nov 2008 → Feb 2009 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 29 sources stand behind the page.

FieldValueCited text
Known as AZD1656 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00819884 ↗
25

NCT00817271 ↗

NCT01221545 ↗

NCT05216172 ↗

NCT00995787 ↗

NCT04516759 ↗

NCT01096940 ↗

NCT00817778 ↗

NCT01083212 ↗

NCT00726427 ↗

NCT00768105 ↗

Show 15 more sources
Action Activate “activating glucokinase in both the pancreas and the liver” PMID 22943931 ↗ Nov 2012
1

“Hexokinase type IV activator” CHEMBL3219124 ↗
Modality Small molecule “The trial suggests a beneficial therapeutic effect of AZD1656 and identifies a new therapeutic concept: small molecule activation of endogenous homeostatic immune cells which...” PMID 35996565 ↗ Aug 2022
Route Oral “single ascending oral doses of AZD1656” NCT00726427 ↗
Target GCK “Hexokinase type IV activator” CHEMBL3219124 ↗